If my goal was simply to match the S&P/ASX 200 Index (ASX: XJO), I could just buy an index exchange-traded fund (ETF) and call it a day.
But if I genuinely want to outperform over the next decade, I think I need exposure to businesses with structural tailwinds, pricing power, and the ability to reinvest capital at high returns.
For me, that means leaning into quality, not speculation.
Here's where I'd focus.
Image source: Getty Images
Structural growth in wealth management
One of the clearest long-term trends in Australia is the shift toward professional financial advice and platform-based wealth management.
That's why I'd want exposure to Hub24 Ltd (ASX: HUB).
Funds under administration continue to grow as advisers migrate to more modern, feature-rich platforms. What excites me is the operating leverage. As scale builds, margins expand. Incremental flows are highly profitable.
If the company keeps executing, I believe earnings growth could exceed the broader market for years.
Global healthcare compounding
Healthcare is another area where I think long-term outperformance is possible.
ResMed Inc (ASX: RMD) gives exposure to global demand for sleep and respiratory care. Ageing populations and increasing diagnosis rates create a long runway.
What I like most is the mix of hardware and high-margin software. Its cloud-connected ecosystem adds recurring revenue and stickiness.
If earnings keep compounding at attractive rates, I think the market will eventually reward that consistency.
High-margin niche technology
I also like niche technology leaders with strong competitive moats.
Pro Medicus Ltd (ASX: PME) is a good example. Its imaging software platform is used by leading hospitals globally, and switching costs are significant.
Concerns about artificial intelligence (AI) disruption have weighed on sentiment. But I think leading providers are more likely to integrate AI into their platforms than be displaced by it.
With long-term contracts, global expansion, and premium margins, this is the type of company I'd back to grow faster than the market over a decade.
Selective exposure to cyclicals with leverage
Outperformance of the ASX 200 Index can also come from well-positioned cyclicals.
Qantas Airways Ltd (ASX: QAN) is one I'd consider for this bucket. Capacity discipline, a newer fleet, and strong loyalty economics have reshaped the business.
If management continues to execute well, earnings could remain strong even if conditions normalise.
The mindset that matters
For me, outperforming the ASX 200 is about owning businesses with durable advantages, letting them compound, and adding capital during volatility rather than panicking.
There will be drawdowns. Some years will disappoint. But over 10 years, I think quality growth tends to win.
Foolish Takeaway
If I genuinely want to beat the ASX 200 over the next decade, I'd focus on structural growth, global reach, and strong competitive positions.
Hub24, ResMed, Pro Medicus, and even selective cyclicals like Qantas represent the kind of mix I believe can outperform. Not every year, but over time.
